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Abstract 
Background Symptoms of digestive dysfunction in patients with Parkinson’s disease (PD) 
occur at all stages of the disease, often preceding the onset of central motor symptoms. On the 
basis of these PD-preceding symptoms it has been proposed that PD could initiate in the gut, 
and that the presence of alpha-synuclein aggregates, or Lewy Bodies (LBs) in the enteric 
nervous system might represent one of the earliest signs of the disease. Following this 
hypothesis, much research has been focused on the digestive tract to unravel the mechanisms 
underlying the onset and progression of PD, with particular attention to the role of alterations 
in enteric neurotransmission in the pathophysiology of intestinal motility disturbances. There 
is also evidence suggesting that the development of central nigrostriatal neurodegeneration is 
associated with the occurrence of gut inflammation, characterized by increments of tissue pro-
inflammatory markers and oxidative stress, which might support conditions of bowel 
neuromotor abnormalities. 
Purpose The present review intends to provide an integrated and critical appraisal of the 
available knowledge on the alterations of enteric neuromuscular pathways regulating gut 
motor activity both in humans and pre-clinical models of PD. Moreover, we will discuss the 
possible involvement of neuro-immune mechanisms in the pathophysiology of aberrant gastro 
intestinal gut transit and neuromuscular activity in the small and large bowel. 
 
Keywords  
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4Pellegrini C. 
 
1. Introduction 
Parkinson's disease (PD) is the second most common neurodegenerative disorder in the 
general population, with a prevalence of 1% at the age of 55 years, which increases with 
aging, resulting in an accumulating burden for healthcare. Nigrostriatal dopaminergic loss of 
neurons, the pathological hallmark of PD, triggers complex functional alterations within the 
basal ganglia circuitry, which then cause typical motor symptoms (tremor, rigidity, 
bradykinesia) (1). However, PD is associated also with other peripheral symptoms, that 
include functional gastrointestinal (GI) abnormalities, consisting mainly of delayed gastric 
emptying, constipation and anorectal dysfunction (2-4). 
GI  motility dysfunction often  precedes the onset of motor symptoms in patients with PD by 
many years (5). Furthermore, Lewy bodies (LBs), the typical α-synuclein (α-syn) positive 
inclusions found in PD  brain, have been detected also in neurons of the myenteric plexus and 
dorsal motor nucleus of the vagus (DMV) of PD patients, suggesting that the underlying 
pathological process involves also the autonomic nervous system (6). Interestingly, Del 
Tredici and colleagues postulated that the gut could represent the starting site of PD, and that 
the presence of LBs in the enteric nervous system (ENS) might be one of the earliest signs of 
the disease (7). In this context, research efforts are currently focused on understanding the 
pathophysiological mechanisms underlying gut neuromuscular dysfunctions associated with 
PD. The present review intends to provide an appraisal of the available knowledge about 
enteric functional, neurochemical and molecular alterations associated with PD. Special 
attention has been paid to the pre-clinical PD models would translate to human PD 
pathophysiology and what role the enteric cell network plays in the pathophysiology of bowel 
disorders associated with PD. 
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2. Intestinal enteric abnormalities in PD patients 
Infrequent bowel movements and constipation represent the main intestinal disturbances in 
patients with PD (8). Such disorders may occur both in the early and advanced stages of the 
disease, worsening the patients’ quality of life (9). There is an increasing recognition of the 
involvement of cells of the enteric neuromuscular compartment in this process (i.e. intrinsic 
primary afferent neurons, enteric glia, interstitial cells of Cajal), that contribute actively to the 
regulation of small bowel functions. A number of clinical investigations have attempted to 
unravel the pathophysiological mechanisms underlying bowel alterations occurring in PD 
patients. Data on neurochemical, molecular and functional enteric changes in PD patients are 
discussed in the following sections and summarized in Table 1. 
 
2.1 Small bowel 
Little is known about the pathophysiology of small bowel dysmotility associated with PD. 
Even though the presence of α-syn accumulation has been detected in duodenal and ileal 
biopsies from PD patients at different stages of the disease, the same biopsies did not reveal 
any myenteric ganglion loss or alterations of nitric oxide (NO), vasoactive intestinal peptide 
(VIP), dopamine and catecholamine neuronal density (10-12). Increasingly, the role of enteric 
luminal microbiota in GI dysfunction associated with brain neurodegenerative and 
inflammatory diseases (i.e. Alzheimer’s disease, PD and multiple sclerosis) is recognized (13, 
14). At present, there is some clinical evidence supporting the contribution of enteric bacteria 
to the alterations of intestinal motility associated with PD. In particular, the occurrence of 
both small intestine bacterial overgrowth (SIBO) and malabsorption syndrome, characterized 
by increased bacterial density in the small bowel, with frequent impairment of GI motility, 
have been observed in PD patients (15, 16). However, the actual involvement of intestinal 
microbial flora in the pathogenesis of GI abnormalities in PD remains to be elucidated and, 
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most importantly, there is a substantial lack of data on the possible role of the brain-gut-
microbiota axis in the pathophysiology of PD. Moreover, it remains unclear whether bacterial 
overgrowth acts as a possible pathophysiological mechanism, or whether it rather occurs as a 
mere consequence of the impaired small bowel motility. These are open issues, which 
represent areas of interest for future investigations. 
 
2.2 Large bowel 
Chronic constipation is the most widely recognized functional gut disorder associated with 
PD. It occurs with a prevalence ranging from 70 to 80% and precedes the onset of movement 
disorders in 87% of PD patients (5), with negative impact on the patient's quality of life and 
increased health care costs. PD patients with constipation are characterized by infrequent 
bowel movements, impairment of propulsive colonic motility and prolonged colonic transit 
time as well as reduced rectal contractions and abnormalities in motor activity of the anal 
sphincter (17).  
The pathogenic mechanisms underlying the development of colonic constipation associated 
with PD are presently unclear, as most, if not all, studies fail to demonstrate changes in the 
neurochemical and/or innervation pattern in intestinal tissue of PD patients. An initial study of 
human colonic morphological and molecular changes associated with PD was provided by 
Singaram et al. (18). These authors performed a detailed quantification of submucosal and 
myenteric dopaminergic neurons by labeling both TH and dopamine. They also assessed the 
density of VIP neurons, substance P and neuropeptide Y. Their results showed that, in the 
submucosal plexus, the number of both TH and dopamine containing neurons did not differ 
from that observed in control tissues, while in the myenteric plexus the number of 
immunopositive neurons for dopamine were reduced, without significant changes in TH 
immunostaining. In both plexuses, there were no significant variations seen in the density of 
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VIP-ergic neurons, SP and neuropeptide Y. The myenteric decrease in the density of 
dopaminergic neurons was associated with a reduced dopamine content in the muscularis 
externa, while no differences were detected in the mucosal layer, suggesting an impairment of 
dopaminergic neurotransmission in the PD human colon (18). Lebouvier et al. (19) confirmed 
the lack of significant changes in the density of submucosal dopaminergic neurons in colonic 
biopsies from PD patients. Subsequent investigations by Annerino et al. (11), consistent with 
the findings reported by Lebouvier et al. (19), did not observe any significant change in the 
proportion of myenteric nitrergic, VIP-ergic or dopaminergic neurons. Likewise, Corbille et 
al. (20) did not found abnormalities in the density of dopaminergic neurons as well as the 
expression levels of dopaminergic and noradrenergic markers in colonic biopsies from PD 
patients. Taken together, most of current evidence suggests that colonic dopamine, nitrergic 
and peptidergic pathways are not significantly affected in PD patients. It is interesting to note 
that neurochemical evidence from non-PD patients with chronic constipation showed distinct 
profiles of neurotransmitter levels in colonic neuromuscular compartment as compared to PD 
patients, characterized by a decreased VIP and substance P expression and enhanced nitrergic 
innervation (21).   
When considering the distribution and localization of LBs and Lewy neurites in colonic 
tissues from PD patients, the presence of α-syn inclusions in colonic neurons has been 
recently documented at all stages of the disease, suggesting that their accumulation could be 
viewed as a biomarker of PD (22). However, clear relationships between colonic α-syn 
accumulation and bowel neuromuscular dysfunctions during PD have not been 
mechanistically established and should be investigated in the near future. 
Over the last years, growing interest has been dedicated to the role played by central and 
peripheral neuroinflammation in the pathophysiology of neurodegenerative diseases (23). Of 
note, recent studies, showing a significant increase in pro-inflammatory cytokine levels and 
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enteric glial activation in colonic biopsies from PD patients, suggest that also enteric 
inflammation could play a key role in the pathogenesis of bowel dysfunctions associated with 
PD (22, 24, 25). In a recent paper, Keshavarzian et al. (26) analyzed the fecal and mucosal 
colonic microbiota compositions and showed that PD patients are characterized by a condition 
of dysbiosis and inflammation. In particular, PD patients displayed decreased abundance of 
“anti-inflammatory” butyrate-producing bacteria, concomitant with increased levels of “pro-
inflammatory” Proteobacteria of the genus Ralstonia, that could contribute to promote bowel 
inflammatory/immune responses during PD (26, 27). In addition, Clairembault et al.(28) have 
observed morphological alterations of the intestinal epithelial barrier, characterized by 
reduced levels of occludin in colonic tissues of PD patients (28). Taken together, these 
observations suggest that alterations of the enteric microbiome, along with changes in 
intestinal permeability, could contribute to the occurrence of intestinal inflammation observed 
in PD patients. 
Overall, current knowledge points out the presence of aggregated α-syn in enteric neurons, 
intestinal dysbiosis and the occurrence of inflammatory activity in colonic tissues of PD 
patients, even though these alterations have not yet been linked to the pathogenesis of colonic 
motor dysfunctions. It remains also to be conclusively demonstrated whether, and to what 
extent, impairment of enteric neurotransmission, as well as the immune/inflammatory 
responses could contribute to colonic dysmotility in PD. 
 
3. Bowel alterations in pre-clinical models of PD 
In an attempt to better understand the pathophysiological mechanisms underlying bowel 
dysmotility occurring in patients with PD, efforts were made to study gut dysfunctions in pre-
clinical models of PD. Current models allow two different approaches: 1) peripheral induction 
of PD-like pathological alterations by systemic administration of neurotoxins; 2) induction of 
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nigrostriatal denervation by central injection of neurotoxins. The main features of PD models 
employed in studies on the evaluation of GI dysfunctions are summarized in Table 2. In the 
following sections, data available on functional, neurochemical and molecular intestinal 
alterations in pre-clinical models of PD are discussed. 
 
3.1 Small bowel 
3.1.1 Functional alterations 
Current evidence, concerning motor dysfunctions occurring in the small intestinal tract in the 
presence of PD, is fragmentary and often conflicting (Table 3). In the peripheral model of 
dopaminergic degeneration induced by 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 
which blocks mitochondrial complex I activity into dopaminergic neurons of the substantia 
nigra pars compacta) in mice, Anderson et al. (29) did not detect any significant alteration in 
small intestinal transit. In PD induced by central injection of toxins, only one study, showing 
alterations of intestinal transit, is available. In particular, a delayed transit in the distal region 
of small bowel has been observed by means of geometric center analysis in rats injected with 
6-OHDA, suggesting that central dopaminergic denervation is associated with impaired small 
bowel motility (30). However, given the paucity of data, extensive investigations are needed 
to better understand the impact of central dopaminergic neurodegeneration on the onset of 
intestinal dysmotility.  
 
3.1.2 Neurochemical and molecular alterations 
3.1.2.1 Inhibitory pathways 
Most of the available knowledge about the alterations of enteric neurotransmission in small 
bowel during PD concerns changes of the dopaminergic network in both peripheral and 
central models of dopaminergic neurodegeneration (Table 3, Figure 1). In particular, mice 
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treated with MPTP displayed a significant decrease in the number of dopamine transporter 
(DAT) and tyrosine hydroxylase (TH)-positive neurons in both myenteric and submucosal 
plexus of the duodenum and ileum (29). Likewise, molecular analysis showed a reduced 
protein expression of TH and DAT in the duodenum of MPTP-treated mice (31). These 
findings are in keeping with a subsequent report by Natale et al. (32), who observed a 
significant reduction of dopamine content in the duodenum of MPTP-treated mice, suggesting 
that this peripheral model is characterized by an impairment of small bowel dopaminergic 
neurotransmission.  
When considering PD elicited by central toxins, only one study examined the alterations of 
dopaminergic markers in intestinal tissues from rats with 6-hydroxydopamine (6-OHDA)-
induced PD. This work showed a significant increase in TH and DAT expression (31), in 
contrast to data obtained from the MPTP model, where a decrease in enteric dopaminergic 
markers was evident. These differential rearrangements of the enteric dopaminergic network 
could depend on intrinsic differences of PD models in different animal species, which might 
also reflect different pathophysiological stages of the disease. 
There is scarce evidence on the neurochemical modifications of enteric nitrergic and VIP-
ergic inhibitory nerve pathways in the presence of PD. Of note, no changes in the number of 
both enteric nitrergic and VIP-ergic neurons were detected upon central denervation induced 
by peripheral toxins (29, 32-34). In the setting of 6-OHDA-induced nigrostriatal neuro-
degeneration, only two studies have examined the possible alterations of nitrergic and VIP-
ergic pathways in the small intestine. Colucci et al. (35) observed a decrease in the density of 
neuronal nitric oxide synthase (nNOS) positive neurons along with an increased percentage of 
VIP-immunoreactive neurons in the myenteric plexus of distal ileum, while Toti and Travagli 
(36) showed an increase in the density of nNOS neurons in the duodenum. These results 
suggest that changes in the expression of nitrergic neuronal markers could vary depending on 
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the intestinal region considered. However, additional investigations are needed to better 
understand the involvement of nitrergic pathways in intestinal dysfunctions associated with 
PD. 
 
3.1.2.2 Excitatory pathways 
Information on the alterations of small bowel cholinergic excitatory neurotransmission in 
experimental models of PD are quite limited and heterogeneous (Table 3). For instance, no 
changes in the number of myenteric cholinergic neurons were observed in the duodenum and 
ileum of mice treated with MPTP (29, 32). In the 6-OHDA model of central dopaminergic 
degeneration, Colucci et al. (35) did not detect any variation in the number of cholinergic 
enteric neurons, while Toti and Travagli (36) reported a decrease of this neuronal population, 
likely as a result of the different bowel regions and timing. Indeed, Toti and Travagli (36) 
performed their experiments on the duodenum 5 weeks after the induction of central 
neurodegeneration, while Colucci et al. (35) performed their assays in the distal ileum from 
rats sacrificed 4 weeks after 6-OHDA injection. Thus, it appears that in this model the 
alterations of enteric cholinergic neurons are more likely to occur in the proximal sections of 
small bowel. 
 
3.1.3 Discussion 
Taken together, current data suggest that in the presence of central dopaminergic 
neurodegeneration the small intestinal transit is impaired, likely as a consequence of 
alterations in the chemical coding of enteric inhibitory neurons. However, there is a lack of 
consistent data concerning the involvement of cholinergic, nitrergic and VIP-ergic pathways 
in small bowel dysfunctions during PD. Likewise, it remains still unclear whether enteric 
dopamine plays a role in intestinal alterations associated with central dopaminergic 
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neurodegeneration, since a characterization on the physiological role of dopamine in the 
control of small bowel motility is still lacking. Furthermore, there is no detailed information 
about the pathophysiological mechanisms underlying the development of intestinal 
dysmotility in PD. Based on this picture, the effects of central neurodegeneration on small 
bowel motor abnormalities remain a field largely opened to future investigations. 
 
3.3 Large bowel 
3.3.1 Functional alterations 
A number of studies have evaluated the abnormalities of colonic motility associated with 
central dopaminergic neurodegeneration (Table 3). Two reports described a delay of in vivo 
colonic transit and constipation in rotenone- and MPTP-induced neurodegeneration in mice 
(32, 33). Functional in vitro experiments demonstrated an increase in contractile activity and 
an impaired relaxation in the proximal colon from MPTP-treated mice, suggesting an 
alteration in the inhibitory control of colonic motility (29, 33). Likewise, in the central 6-
OHDA model, a significant decrease in stool frequency and delay in colonic transit were 
detected (37, 38). In addition, an ex-vivo analysis of peristalsis displayed an altered pattern of 
colonic longitudinal muscle contraction and a reduced peak pressure, suggesting that central 
dopaminergic neurodegeneration is associated with an impairment of colonic motility 
resulting in a reduced efficiency of the peristaltic reflex (35). These findings have been 
corroborated by recent in vitro functional studies, showing an impairment of colonic 
spontaneous contraction and a decrease in electrically evoked cholinergic contractions of both 
longitudinal and circular colonic smooth muscle from 6-OHDA rats (38, 39). However, in the 
same model, Pellegrini et al. (40) described also an enhanced in vitro longitudinal colonic 
tachykininergic contractile activity. This apparent discrepancy with a reduced peristaltic 
activity can be explained by the fact that the patterns of in vivo colonic transit do not 
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necessarily reflect the contractile responses elicited by specific stimulation of the excitatory 
tachykininergic pathway, but rather can be viewed as a result of an integrated combination of 
smooth muscle contractions regulated by both excitatory and inhibitory neurotransmitter 
pathways. 
 
3.2 Neurochemical and molecular alterations 
3.2.1 Inhibitory pathways 
Changes in both inhibitory and excitatory enteric pathways regulating colonic motility in 
experimental PD have been evaluated by morphological investigations (Table 3). In the PD 
model elicited by rotenone (an isoflavone insecticide), no changes in nitrergic, VIP-ergic and 
dopaminergic enteric neuron number or innervation quality were detected (33). By contrast, in 
the setting of PD induced by intranigral injection of 6-OHDA, alterations of inhibitory enteric 
pathways were observed. In particular, increments of VIP-ergic and dopaminergic neurons in 
concomitance with a decrease in nitrergic neurons were detected in the proximal colon (35, 
37, 41). Colucci et al. (35) showed that dopamine D2 receptors were mostly expressed in 
enteric cholinergic and dopaminergic neurons, and that their immunoreactivity was markedly 
reduced in myenteric neurons of both proximal and distal colon. In addition, in two previous 
studies (39, 42) an increase in dopamine content was observed in the colonic muscularis 
externa of 6-OHDA rats, which could contribute to colonic dysmotility in PD. Zhang et al. 
(39) observed also an increase in adrenergic β3 receptor expression and a decreased expression 
of serotoninergic 5-HT4 receptors, suggesting that neurochemical and molecular changes 
affecting the enteric pathways might contribute to colonic dysmotility and constipation 
displayed by 6-OHDA rats. 
Additional support to the concept that alterations of inhibitory dopaminergic and nitrergic 
pathways can contribute to the occurrence of colonic dysfunctions associated with 
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experimental PD has been provided by molecular studies. When considering the 
dopaminergic network, a study by Tian et al. (31) showed that, in the MPTP mouse model, 
the colonic TH protein levels were decreased, while in the 6-OHDA rat model an increase in 
the protein levels of TH and DAT was found. The latter observations are consistent with those 
reported by Zhu et al. (37), who showed an increase in TH protein levels in the proximal 
colon of 6-OHDA rats, suggesting that differential changes in the colonic dopaminergic 
system can occur depending on the different experimental models of PD. Interestingly, central 
dopaminergic denervation is associated also with an impairment of colonic nitrergic 
pathways, as documented by a significant decrease in nNOS protein levels in the proximal 
colon of PD rats (37). 
 
3.2.1 Excitatory pathways 
At present, there is inconsistent data on putative changes occurring in the colonic excitatory 
cholinergic system during PD (Table 3, Figure 2). Only one study has shown alterations of 
cholinergic enteric neurons in the PD model induced by peripheral toxins. In particular, in the 
rotenone model, ChAT immunoreactivity was significantly decreased in the myenteric plexus 
after 1 and 6 weeks from toxin infusion (43). When considering PD induced by 6-OHDA, the 
evidence showing changes in the cholinergic excitatory pathway are fragmentary and 
conflicting. Two studies did not show alterations in the density of ChAT-positive neurons, as 
well as in ChAT protein and mRNA expression levels in the proximal colon from 6-OHDA 
rats (35, 37). Conversely, in a recent paper by Fornai et al. (38) a decrease in ChAT immune 
positivity in the distal colon of 6-OHDA rats was detected. Furthermore, a significant 
decrease in acetylcholine release from colonic preparations was observed, suggesting an 
impairment of colonic cholinergic neurotransmission in the presence of central dopaminergic 
neurodegeneration. In the same study, additional molecular analysis showed an increased 
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expression of muscarinic M2 and M3 receptors in the colonic neuromuscular layer and isolated 
colonic smooth muscle cells from 6-OHDA rats, thus indicating an up-regulation of muscular 
muscarinic receptors as a compensatory response to the impairment of cholinergic 
neurotransmission (38). Consistently with these findings, in vitro functional experiments 
displayed an impaired colonic motility in PD rats (38). More recently, Pellegrini et al. (40) 
observed significant changes in the tachykininergic pathway of the colonic neuromuscular 
layer from 6-OHDA rats. In particular, nigrostriatal degeneration was followed by an increase 
in endogenous substance P expression in myenteric ganglionic neurons, along with an 
enhancement of NK1 receptors in longitudinal muscle cells, thus indicating that the enteric 
excitatory tachykininergic pathway can be affected also by central dopaminergic 
neurodegeneration. 
 
3.1.3 Discussion 
An overall appraisal of current data suggest that nigrostriatal neurodegeneration is followed 
by an impairment of distal colonic motility, leading to a reduced efficiency of peristaltic 
reflex. Such alterations seem to result from a rearrangement in the chemical coding of enteric 
inhibitory and excitatory neurons, since a loss of neurons in the colonic myenteric plexus has 
not been detected (38). In particular, the impairment of cholinergic neurotransmission appears 
to playa significant role in the onset of colonic dysmotility during PD. However, the roles 
played by enteric nitrergic and dopaminergic neurotransmission in colonic dysmotility 
associated with PD remains scarcely understood and deserve further investigations. 
 
4. Overall conclusions and future directions 
Human studies and evidence from pre-clinical models suggest that PD is associated with 
significant functional, neurochemical and molecular alterations throughout the intestinal tract. 
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Studies in animal models support the view that intestinal motor abnormalities are associated 
with changes in the neurochemical coding of myenteric neurons, both in the small and large 
bowel. Most of functional pre-clinical findings are consistent with bowel dysfunctions 
observed in patients with PD, even though current morphological and molecular data on both 
inhibitory and excitatory pathways regulating enteric motility are fragmentary and often 
conflicting. In addition, a detailed characterization of abnormalities of bowel motor pathways 
occurring in PD is lacking. It remains also unclear whether the occurrence of rearrangements 
in the enteric neuronal network and intestinal dysfunctions are direct consequences of the 
central neurodegeneration or could represent the starting point of the disease. In this respect, a 
crucial role seems to be played by the neuro-immune brain-gut axis, particularly for DMV, 
that provides parasympathetic innervation to the majority of GI tract and is regarded as one of 
the two CNS sites displaying the earliest pathological involvement in PD (44). Indeed, the 
functional and neurochemical changes affecting the ENS, following central dopaminergic 
denervation, have been shown to directly result from alterations occurring in the DMV, which 
is modulated by brainstem dopaminergic circuitries and represents a prominent target of 
neurodegenerative PD-related processes (45, 46). In support of this view, a reduced 
expression of ChAT in the DMV of rats with 6-OHDA-induced PD and a reduced digestive 
motor activity have been reported. In addition, when animals were subjected to vagotomy, the 
digestive dysmotility improved, thus suggesting that gut dysfunctions in PD could depend on 
the impairment of vagal brain-gut axis (47). 
The vagus nerve is referred also as the “cholinergic anti-inflammatory pathway”, since it 
seems to exert tonic anti-inflammatory actions, while vagotomy confers an increased 
susceptibility to the development of inflammatory motility disturbances (48). In the setting of 
PD, two recent pioneering studies, performed both in colonic biopsies from PD patients and 
colonic tissues from 6-OHDA-induced PD in rats, have shown an increase in pro-
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inflammatory cytokine levels and enteric glial activation (24, 40). In addition, the pre-clinical 
study demonstrated also an increase in colonic tissue oxidation, an increment of neutrophil 
and mast cell density, and a polarization of peritoneal macrophages towards a pro-
inflammatory phenotype (40). These results suggest the occurrence of an inflammatory 
condition in the gut during PD, which could result from an impairment in the vagal brain-gut 
axis, and might contribute to generate or worsen enteric dysfunctions related to central 
neurodegeneration (24). Since the extrinsic vagal impairment is expected to affect the overall 
bowel functions, the development of tissue inflammatory response should affect the whole 
intestinal tract. On the other hand, as in the CNS, changes in the ENS of PD patients or 
animal models might be restricted to functionally specific and limited bowel regions or 
ganglia, and this outcome might increase the likelihood of under- or over-estimating the 
actual gut alterations. However, current state of the art does not allow to accept or rule out any 
of the above hypotheses, and therefore this issue remains open to future investigations aimed 
at evaluating the molecular, morphological and functional changes occurring in different 
intestinal regions, at different time points, in different experimental models and PD patients. 
In conclusion, current knowledge encourages research efforts dedicated to clarify the role 
played by neuro-immune brain-gut axis in the pathogenesis of gut motor dysfunctions in PD. 
In particular, it appears of primary relevance to investigate whether gut neuro-inflammation is 
a consequence of the impairment of vagal cholinergic anti-inflammatory pathway, and 
whether such a condition could be responsible for the alterations of gut motor pathways 
occurring in the presence of central dopaminergic neurodegeneration. 
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Table 1. Functional, neurochemical and molecular alterations associated with bowel disorders 
in PD patients 
 
Region Disorder Observations Ref. 
 
 
 
Small 
bowel 
 
 
 
Dysmotility 
 α-syn accumulation in mucosal submucosal nerve fibres and 
myenteric ganglia of duodenum and ileum 
   No alterations of nitrergic, VIPergic, dopaminergic and adrenergic 
neuron density in myenteric neurons 
 Small intestine bacteria overgrowth 
 
[10] 
[11] 
[12] 
[16] 
 
 
 
 
 
Large 
bowel 
 
 
 
Constipation 
Anorectal 
dysfunction 
 
 Reduction of dopamine levels in submucosal and myenteric plexus 
 No alterations of neuronal density in submucosal and myenteric 
plexus  
 No alterations of nitrergic, VIPergic, dopaminergic and adrenergic 
neuron density in myenteric neurons 
 Aggregated α-syn in cholinergic and substance P-containing neurons 
in submucosal and mucosal biopsies  
 Increase in cytokine levels (TNF, IL-1β, IL-6, IFN-γ) and enteric 
glial activation (GFAP and Sox-10)  
 
[11] 
[18] 
[19] 
[24] 
[25] 
[49] 
[50] 
 
 
Abbreviations: α-syn: α-synuclein; GFAP: glial fibrillary acidic protein; IL-1β: interleukin 1 beta; IL-6: 
interleukin-6; IFN-γ: interferon gamma; Sox-10: sex determining region Y (SRY) box containing gene 10; TNF: 
tumor necrosis factor; VIP: vasoactive intestinal peptide.  
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Table 2. Main features of experimental models employed in the evaluation of bowel 
alterations associated with central dopaminergic neurodegeneration 
Experimental models Functional, neurochemical and molecular characteristics Ref. 
 
 
 
Neurodegeneration 
induced by peripheral 
toxin administration 
 
 
MPTP 
 Blockade of mitochondrial complex I in SNpc 
 Loss of dopaminergic neurons  in  the  SNpc 
 Intraperitoneal administration not associated with formation of 
LB-like cytoplasmic inclusions 
 Administration via osmotic minipumps followed by formation 
of LB-like cytoplasmic inclusions containing ubiquitin and α-
syn 
[51] 
 
 
Rotenone 
 Different routes of administration (oral, intraperitoneal, 
intravenous and systemic by osmotic pump) 
 Degeneration of nigrostriatal dopaminergic neurons 
 Blockade of mitochondrial electron transport chain 
 Increase in oxidative stress  
 Inhibition of proteasome activity 
 LB-like cytoplasmic inclusions containing ubiquitin and α-syn 
[51] 
[52] 
[53] 
Neurodegeneration 
induced by intranigral 
toxin administration 
 
6-OHDA 
 Bilateral or unilateral intranigral administration  
 Massive anterograde degeneration of the nigrostriatal pathway 
(nigral cell loss and striatal dopamine depletion) 
 Increase in hydrogen peroxide formation 
 Inhibition of mitochondrial complex I in SNpc 
[54] 
 
Abbreviations: α-syn: α-synuclein; LB: Lewybodies; MPTP: 1-methyl-4-phenil-1,2,3,6,tetrahydropyridine; 6-
OHDA: 6-hydroxydopamine; SNpc: substantia nigra pars compacta 
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Table 3. Summary of functional, neurochemical and molecular evidence in the small and large 
bowel associated with central dopaminergic neurodegeneration 
Experiment
al models 
(Species) 
Functional evidence Neurochemical evidence Molecular evidence Ref. 
Small bowel 
 
MPTP 
(mouse) 
Reduced myoelectric 
activity 
Prolonged irregular 
contractions  
No alterations of 
overall transit 
  TH  
   DAT 
  No alterations  of VIP 
  No alterations  of NET 
TH protein expression 
DAT protein expression 
DA concentration  
[29] 
[31] 
[32] 
 
 
Unilateral 
intranigral 
injection of 
6-OHDA 
(rat) 
 
 
 Reduced transit 
 nNOS (distal ileum) 
 nNOS (duodenum) 
   VIP 
No alterations  of ChAT (distal ileum) 
 ChAT (duodenum) 
  No alterations  of HuC/D  expression 
TH protein expression 
DAT protein expression  
[31] 
[35] 
[36] 
Large bowel 
 
MPTP 
(mouse) 
Delay of transit  
Impaired inhibitory 
control of motility 
 
n.a 
TH protein expression [29] 
[31] 
[32] 
 
Rotenone 
(mouse) 
Delay of transit  No alterations  of VIP 
No alterations  of NOS 
No alterations  of TH 
 
n.a. 
[33] 
 
 
Unilateral 
intranigral 
injection of 
6-OHDA 
(rat) 
Decrease in stool 
frequency  
Delayed colonic transit 
Reduced efficiency of 
peristaltic        reflex  
Alterations of  
longitudinal muscle 
contraction 
Decrease in electrically 
evoked cholinergic 
contractions  
       VIP  
       TH 
       nNOS 
       D2 dopaminergic receptors 
 No alteration  of ChAT (proximal colon) 
       ChAT (distal colon) 
     TH protein expression 
     DAT protein expression 
     nNOS protein expression 
     nNOS mRNA expression  
     ChATimmunopositivity  
     Acetylcholine release from 
enteric neurons 
      M2 and M3 muscarinic receptor 
expression 
[29] 
[35] 
[37] 
[38] 
[41] 
 
Abbreviations: ChAT: choline acetyltransferase; DAT: dopamine transporter; DA: dopamine; NET: 
noradrenaline transporter; nNOS: neuronal nitric oxide synthase; TH: tyrosine hydroxylase; VIP: vasoactive 
intestinal peptide; n.a: data not available. 
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Figure legends 
 
Figure 1. Schematic illustration of small bowel abnormalities in experimental models of 
Parkinson’s disease (PD). Left panel: central dopaminergic denervation, induced by 
intranigral toxins injection, is associated with an increase in choline acetyl transferase (ChAT) 
and nitric oxide (NO) expression in myenteric neurons of duodenum. In the distal ileum, the 
expression of tyrosine hydroxylase (TH), dopamine transporter (DAT) and vasoactive 
intestinal peptide (VIP) is increased in both myenteric and submucosal plexus, while the 
expression of neuronal nitric oxide synthase (nNOS) is decreased in myenteric neurons. The 
overall small intestinal transit is reduced. Right panel: central dopaminergic denervation 
induced by peripheral toxins injection is associated with a decrease in DAT and TH 
expression in both myenteric and submucosal plexus of duodenum and ileum. No changes in 
small intestinal transit have been reported. 
 
Figure 2. Representative picture showing changes in colonic cholinergic neurotransmission in 
the presence of central dopaminergic denervation elicited by 6-OHDA. The expression of 
choline acetyltransferase (ChAT) in myenteric plexus is decreased, as well as acetylcholine 
release from colonic myenteric nerves, in comparison with normal animals. The expression of 
muscarinic M2 and M3 receptors in the colonic smooth muscle layer is enhanced. The colonic 
motor activity is impaired. 


